Amyl Therapeutics closes €18.3 million Series A financing to develop novel therapies for Amyloidosis

Corporate Breaking News

Home : Amyl Therapeutics closes €18.3 million Series A financing to develop novel therapies for Amyloidosis

Jun 03 2021	Amyl Therapeutics closes €18.3 million Series A financing to develop novel therapies for Amyloidosis
LIEGE, Belgium, June 3, 2021 /PRNewswire/ -- Amyl Therapeutics ('Amyl'), a preclinical stage biotechnology company developing its amyloid fibrils specific technology platform named ClariTY for the treatment of all forms of Amyloidosis, today announced that it has successfully closed a €18....


Source:http://prnmedia.prnewswire.com/news-releases/amyl-therapeutics-closes-18-3-million-series-a-financing-to-develop-novel-therapies-for-amyloidosis-301304349.html

Related News
» GIGABYTE Introduces First Eyesafe Gaming Monitors » Viasat Ramps Satellite Services in the Middle East and Western Europe Ahead of ViaSat-3 Launch; Signs Ka-Band Capacity Lease Deal with Avanti Communications